GSK Gains FDA Approval for Hibsago, Therapy for Chronic Hepatitis B in Adults

GSK's approval of Hibsago (bepirovirsen) on October 20, 2026 introduces the first antisense oligonucleotide (ASO) modality into the chronic HBV treatment landscape, carrying with it a companion diagnostic requirement and a boxed warning that will shape how manufacturers, QA teams, and regulatory affairs leads approach labeling, pharmacovigilance, and patient-selection protocols from day one.

The FDA approved Hibsago as an adjunct to existing antiviral therapy for adults without cirrhosis who have maintained HBV suppression for at least six months and present with hepatitis B surface antigen (HBsAg) levels at or below 3,000 IU/mL. That eligibility threshold is not discretionary: patient selection must be confirmed using an FDA-authorized companion diagnostic, specifically the Roche Elecsys HBsAg II Quant II RxDx assay, authorized concurrently with the drug. For regulatory teams, this dual-authorization structure creates a linked compliance obligation, drug labeling and diagnostic labeling must remain aligned through any post-approval changes.

The boxed warning covers two primary risks: serious hepatic reactions and thrombocytopenia, the latter carrying potential for life-threatening hemorrhage. Additional labeled warnings address nephrotoxicity, serious inflammatory reactions including vasculitis, and injection-site risks tied to improper administration technique. The monitoring requirements are substantive: patients require regular hematologic and renal laboratory assessments before and throughout the 24-week subcutaneous dosing period, with antiviral co-therapy continuing for at least 24 weeks post-final injection. QA and pharmacovigilance functions will need to build out signal-detection frameworks that account for this extended post-treatment observation window.

Efficacy data from two placebo-controlled trials showed that 24% of Hibsago-treated patients met criteria to discontinue background antiviral therapy, versus none on placebo. At 24 weeks post-cessation of all HBV treatment, 19% of Hibsago recipients maintained viral control with undetectable HBsAg, a functional cure endpoint that the field has pursued for years. The regimen's complexity, including conditional treatment discontinuation based on lab thresholds, will require clear procedural documentation at the prescribing and dispensing level to remain consistent with 21 CFR Part 201 labeling obligations.

Hibsago received Fast Track, Breakthrough Therapy, and Priority Review designations, reflecting the unmet need in a population for whom indefinite antiviral suppression has been the only available strategy. For manufacturers entering the ASO therapeutic class, this approval sets a regulatory precedent on how companion diagnostics, boxed warnings, and conditional discontinuation criteria will be structured and enforced.

The 24-week post-treatment durability rate of 19% will serve as the baseline comparator as GSK's post-marketing commitments and any label update negotiations with FDA unfold.

Source: U.S. Food and Drug Administration via FDA.gov press announcement, October 20, 2026.